Runda medical issues substantial guarantees for subsidiary growth

Runda Medical Technology (SSE:603108) has issued guarantees totaling RMB 234,339.58 million for its wholly-owned and controlling subsidiaries as of the end of last month. These guarantees are provided to support project construction and daily operations, aligning with the company's overall development strategy. The company’s board approved these guarantees, which fall within the scope of authority granted by the 2024 Annual General Meeting, allowing for up to RMB 422,100 million in credit line guarantees for its subsidiaries to financial institutions.

For November 2025 alone, new guarantees amounted to RMB 36,108.03 million. Several subsidiaries, including Hangzhou Runda Medical Management, Anhui Zefen Biotechnology, Shanghai Runda Rongjia Biotechnology, and Hangzhou Huizhong Diagnostics Technology, have asset-liability ratios exceeding 70%, making these guarantees crucial for their financing needs. The company maintains real-time monitoring of cash flows and financial changes to manage risk, with other shareholders of controlling subsidiaries providing counter-guarantees or full anti-guarantees.

As of the date of this announcement, the total external guarantees by Runda Medical and its controlling subsidiaries amount to RMB 512,100.00 million, representing 117.60% of the company's net assets as of December 31, 2024. The actual outstanding guarantee balance is RMB 312,434.27 million, accounting for 71.75% of the company's audited net assets as of December 31, 2024, with no overdue guarantees reported.